Oncology and Solid Tumor Research

At Spital Clinic Militar De Urgenta Dr. Constantin Papilian Cluj Napoca, the clinical trial portfolio is centered on neoplasms, with studies exploring new treatment options for advanced and metastatic cancers. The research focuses on improving cancer therapy, evaluating safety and early effectiveness, and comparing emerging approaches with established care.

  • Advanced solid tumors and immunotherapy-naive recurrent or metastatic disease
  • Metastatic clear cell renal cell carcinoma
  • ER+, HER2- metastatic breast cancer after endocrine and CDK 4/6 inhibitor therapy

These trials are designed to help identify better ways to control disease progression and expand treatment choices for patients with difficult-to-treat cancers.

Breast Cancer Clinical Research

The site is also involved in studies for both hormone receptor-positive breast cancer and HER2-positive breast cancer, covering early-stage, locally advanced, and metastatic disease. This work aims to assess new therapies and refine treatment strategies for patients with limited options after standard care.

  • ER+, HER2- advanced or metastatic breast cancer
  • HR-negative, HER2-positive early-stage or locally advanced breast cancer
  • Testing new and comparative treatment approaches in breast cancer

Research in this area is focused on treatment effectiveness, safety, and the potential to improve outcomes across different breast cancer subtypes.

Lung Cancer and Targeted Treatment Studies

Clinical trials at this hospital include research in non-small cell lung cancer, especially disease that is HER2 overexpressing and advanced or metastatic. The studies are evaluating combination treatment approaches to better manage cancer growth and improve patient outcomes.

  • Unresectable or metastatic HER2 overexpressing non-squamous non-small cell lung cancer
  • Comparing new combination regimens with standard treatment
  • Assessing progression-free survival and overall treatment benefit

This reflects a strong interest in developing more effective options for patients with advanced lung cancer.

Immune System Diseases and Immunotherapy Research

Another important area involves immune system diseases and the use of immunotherapy in cancer care. The trials are examining how patients respond to immune-based treatments and whether new approaches can improve safety, tolerability, and disease control.

  • Immune checkpoint inhibitor-naive solid tumors
  • Previously treated metastatic cancers receiving immune-based therapy
  • Evaluating treatment response and clinical benefit

These studies support the broader effort to make immunotherapy more effective and accessible for patients with advanced malignancies.

Cardiovascular, Metabolism, and Treatment Delivery Research

Although the main focus remains oncology, the trial landscape also touches on cardiovascular diseases, metabolism, and physiological processes through studies that examine how therapies are delivered and how the body responds to them. This includes work aimed at improving convenience, consistency, and overall treatment experience.

  • Subcutaneous versus intravenous administration of nivolumab
  • Assessing pharmacokinetic performance and treatment practicality
  • Supporting more patient-friendly cancer care approaches

At this Romanian hospital, such research adds a practical dimension to cancer trials by looking at how treatments can be delivered more efficiently without compromising care.